cp-55,940 has been researched along with jwh-133 in 7 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (42.86) | 29.6817 |
| 2010's | 4 (57.14) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chavatte, P; Depreux, P; Farce, A; Goossens, JF; Hénichart, JP; Lambert, DM; Millet, R; Muccioli, GG; Poupaert, JH; Stern, E | 1 |
| Gynther, J; Järvinen, T; Lahtela-Kakkonen, M; Laitinen, JT; Nevalainen, T; Parkkari, T; Poso, A; Salo, OM; Savinainen, JR | 1 |
| Bosier, B; Depreux, P; Goossens, JF; Hamtiaux, L; Hénichart, JP; Lambert, DM; Millet, R; Muccioli, GG; Poupaert, JH; Stern, E | 1 |
| Allen, JG; Babij, P; Fotsch, C | 1 |
| Brogi, S; Corelli, F; Di Marzo, V; Ligresti, A; Mugnaini, C; Pasquini, S; Tafi, A | 1 |
| Buzard, DJ; Han, S; Jones, RM; Thatte, J | 1 |
| Carrillo-Salinas, FJ; Fernández-Ruiz, J; Franco, R; Gómez-Cañas, M; Goya, P; Guaza, C; Hurst, DP; Jagerovic, N; Lagartera, L; Morales, P; Navarro, G; Pazos, R; Reggio, PH | 1 |
2 review(s) available for cp-55,940 and jwh-133
| Article | Year |
|---|---|
Emerging targets in osteoporosis disease modification.
Topics: Animals; Biomarkers; Bone Density; Bone Resorption; Humans; Osteoporosis | 2010 |
Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists.
Topics: Animals; Drug Design; Humans; Ligands; Models, Molecular; Molecular Conformation; Receptor, Cannabinoid, CB2; Structure-Activity Relationship; Substrate Specificity | 2013 |
5 other study(ies) available for cp-55,940 and jwh-133
| Article | Year |
|---|---|
Novel 4-oxo-1,4-dihydroquinoline-3-carboxamide derivatives as new CB2 cannabinoid receptors agonists: synthesis, pharmacological properties and molecular modeling.
Topics: Crystallography, X-Ray; Humans; Models, Molecular; Molecular Structure; Quinolones; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2006 |
3D-QSAR studies on cannabinoid CB1 receptor agonists: G-protein activation as biological data.
Topics: Animals; Cannabinoid Receptor Modulators; Cerebellum; GTP-Binding Proteins; In Vitro Techniques; Ligands; Male; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; Radioligand Assay; Rats; Rats, Wistar; Receptor, Cannabinoid, CB1 | 2006 |
Pharmacomodulations around the 4-oxo-1,4-dihydroquinoline-3-carboxamides, a class of potent CB2-selective cannabinoid receptor ligands: consequences in receptor affinity and functionality.
Topics: Amides; Animals; Binding, Competitive; CHO Cells; Cricetinae; Cricetulus; Drug Inverse Agonism; Humans; Ligands; Quinolines; Radioligand Assay; Receptor, Cannabinoid, CB2; Stereoisomerism; Structure-Activity Relationship | 2007 |
Three-dimensional quantitative structure-selectivity relationships analysis guided rational design of a highly selective ligand for the cannabinoid receptor 2.
Topics: Computer Simulation; Drug Design; Humans; Ligands; Models, Molecular; Molecular Structure; Quantitative Structure-Activity Relationship; Quinolones; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Recombinant Proteins; Stereoisomerism | 2011 |
Chromenopyrazole, a Versatile Cannabinoid Scaffold with in Vivo Activity in a Model of Multiple Sclerosis.
Topics: Dose-Response Relationship, Drug; HEK293 Cells; Humans; Models, Molecular; Molecular Structure; Multiple Sclerosis; Pyrazoles; Receptor, Cannabinoid, CB1; Receptor, Cannabinoid, CB2; Structure-Activity Relationship | 2016 |